Clearmind Medicine
CMND
2 hedge funds and large institutions have $256K invested in Clearmind Medicine in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
73% more capital invested
Capital invested by funds: $148K → $256K (+$108K)
7.13% more ownership
Funds ownership: 1.9% → 9.03% (+7.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$667K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$333K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$140K |
| 2 |
Morgan Stanley
New York
|
-$2.21K |
CMND Hedge Fund Activity: Q1 2023 in Review
2 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Clearmind Medicine (CMND) for Q1 2023, worth a combined $256K — up 73% from $148K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CMND positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was AdvisorShares Investments, opening a new position worth an estimated $667K. The largest seller was Walleye Capital, cutting an estimated $140K.
- 2 institutional investors held Clearmind Medicine (CMND) as of Q1 2023, up from 0 in Q4 2022.
- Funds reported $256K of Clearmind Medicine stock for Q1 2023, up 73% quarter-over-quarter.
- 2 funds opened new Clearmind Medicine positions in Q1 2023 and 0 closed out, a net change of +2 holders.
- The largest Clearmind Medicine buyer in Q1 2023 was AdvisorShares Investments, an estimated $667K added.
- The largest Clearmind Medicine seller in Q1 2023 was Walleye Capital, an estimated $140K sold.
Based on aggregated 13F filings for Q1 2023.